Biogen Idec Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
341.24
-2.12 (-0.62%)
After Hours: 341.24 0.00 (0.00%)
Aug 28, 6:35PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 339.52 - 343.83
52 week 206.60 - 358.89
Open 341.14
Vol / Avg. 644,897.00/1.22M
Mkt cap 81.08B
P/E 37.93
Div/yield     -
EPS 9.00
Shares 236.14M
Beta 1.21
Inst. own 92%
Oct 27, 2014
Q3 2014 Biogen Idec Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 23, 2014
Iraqi Islamic Bank for Investment and Development Annual Shareholders Meeting (Estimated) - 3:00AM EDT - Add to calendar
Sep 4, 2014
Biogen Idec Inc at Citi Biotech Conference - 10:00AM EDT - Add to calendar
Jul 23, 2014
Q2 2014 Biogen Idec Inc. Earnings Release
Jul 23, 2014
Q2 2014 Biogen Idec Inc Earnings Call - Webcast
Jul 19, 2014
Iraqi Islamic Bank for Investment and Development Annual Shareholders Meeting
Jun 12, 2014
Biogen Idec Inc. Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 29.94% 27.11%
Operating margin 40.83% 36.25%
EBITD margin - 43.59%
Return on average assets 23.13% 17.09%
Return on average equity 30.65% 23.90%
Employees 6,850 -
CDP Score - 92 B

Address

225 BINNEY STREET
CAMBRIDGE, MA 2142
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company�s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 55
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
John G. Cox Executive Vice President - Pharmaceutical Operations and Technology
Age: 51
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 59
Bio & Compensation  - Reuters
Tony Kingsley Executive Vice President - Global Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Executive Vice President - Research and Development
Age: 56
Bio & Compensation  - Reuters
Spyros Artavanis-Tsakonas Ph.D. Senior Vice President, Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters